BU
SRPT icon

BBVA USA’s Sarepta Therapeutics SRPT Stock Holding History

BBVA USA’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$70K Sell
753
-406
-35% -$31.3K ﹤0.01% 601
2021
Q2 		$90K Buy
+1,159
New +$87.9K 0.01% 570

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBVA USA's SRPT Position: Q3 2021 in Review

BBVA USA reduced its Sarepta Therapeutics (SRPT) stake by 35% in Q3 2021, selling an estimated $31.3K and leaving 753 shares worth $70K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

BBVA USA first reported a position in SRPT in Q2 2021 and has held it in 2 quarters since. The position peaked at $90K in Q2 2021. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • BBVA USA held 753 shares of Sarepta Therapeutics worth $70K as of Q3 2021.
  • BBVA USA sold 406 Sarepta Therapeutics shares in Q3 2021, an estimated $31.3K.
  • Sarepta Therapeutics made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #601 holding.
  • BBVA USA first reported a position in Sarepta Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Sarepta Therapeutics position peaked at $90K in Q2 2021.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.